ICAD INC. - COMMON STOCK

iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium

11 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation

09 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting

08 Apr 2024 15:29:22 By Nasdaq GlobeNewswire

iCAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)

03 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

iCAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise Scale

02 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists

19 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results

12 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings

28 Feb 2024 07:05:00 By Nasdaq GlobeNewswire

iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)

27 Feb 2024 08:05:00 By Nasdaq GlobeNewswire

iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

27 Feb 2024 07:05:00 By Nasdaq GlobeNewswire

iCAD to Participate in the BTIG at Snowbird: 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

06 Feb 2024 07:00:01 By Nasdaq GlobeNewswire

iCAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member

30 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

iCAD Expands Executive Sales Leadership Team as Business Grows

18 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease

27 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

iCAD and CancerIQ Announce Partnership to Integrate AI-Enabled Technology With Best-in-Class Risk Assessment and Care Management Platform Offering A Comprehensive Breast Health Care Solution  

20 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

iCAD to Participate in the 14th Annual Craig-Hallum Alpha Select Conference

14 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

iCAD Reports Financial Results for Third Quarter Ended September 30, 2023

13 Nov 2023 15:01:00 By Nasdaq GlobeNewswire

iCAD to Report Third Quarter 2023 Financial Results on November 13, 2023

30 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to Elekta

23 Oct 2023 07:01:00 By Nasdaq GlobeNewswire

Health Canada Grants Device License for iCAD's ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year Assessment

16 Aug 2023 07:00:00 By Nasdaq GlobeNewswire